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Abstract
Background: Hashimoto’s encephalopathy is a neuropsychiatric disease with symptoms of cognitive impairment,
stroke-like episodes, seizures, and psychotic or affective symptoms associated with autoimmune thyroiditis and
excellent steroid responsiveness; therefore, it is also called “steroid responsive encephalopathy associated with
autoimmune thyroiditis” (SREAT).
Case presentation: We present the case of a 50-year-old woman who developed a first-onset depressive syndrome
with predominant cognitive impairment and inability to work. Antidepressive treatment and cognitive behavioral
therapy over two years were unsuccessful. Neurological examination was unremarkable. Serum analysis showed
increased thyroid peroxidase and thyroglobulin antibodies. Cerebrospinal fluid protein and albumin quotient
were increased. Magnetic resonance imaging depicted unspecific, supratentorial white matter lesions and frontal
accentuated brain atrophy. Electroencephalography was normal. Neuropsychological testing for attentional
performance was below average. High-dose intravenous treatment with methylprednisolone over 5 days and oral dose
reduction over 3 weeks led to the sustained improvement of clinical symptoms. Following discharge from the hospital,
the patient returned to work, and 6.5 months after the start of therapy, no neuropsychological deficit remained.
Conclusion: This case report illustrates that SREAT might present with purely depressive symptoms, thus mimicking
classical major depression. In such cases, corticosteroid therapy may be an effective treatment option.
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Background
Hashimoto's encephalopathy is a neuropsychiatric disease
with symptoms of cognitive impairment, stroke-like
episodes including transient aphasia, tremor, myoclonus,
gait disorders, or seizures [1]. It is associated with auto-
immune thyroiditis and excellent steroid responsiveness
and is therefore also called “steroid responsive encephal-
opathy associated with autoimmune thyroiditis” (SREAT).
Usually, thyroid hormone abnormalities and, in particular,
anti-thyroid peroxidase (TPO) and thyroglobulin (TG)
antibodies are found. Here, we present the case of a
patient with SREAT suffering from typical psychomotor
and neurocognitive symptoms of a major depression,
while neurological sequelae were absent. This case
illustrates that SREAT without neurological deficits and
with normal thyroid hormones can mimic major depres-
sion. It is important to be aware of this possible association
between symptoms of the most common psychiatric
disease (major depression) and the most frequent
autoimmune disease (Hashimoto thyroiditis), because it
implies specific and more causal treatment options, such
as corticosteroids.
Case presentation
We present the case of a 50-year-old female receptionist
who, early in 2011, developed loss of energy and feelings
of exhaustion but without any identified psychosocial
stressors. At the end of the same year, she presented
with a classical depressive syndrome (suffering from
impaired concentration, slowed thinking processes,
disturbed memory, low mood, decreased activity, reduced
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energy, fearfulness, symptoms of demoralization with
hopelessness, reduced self-awareness, excessive guilty,
sleep disturbance, inability to work, and social withdrawal).
For the patient, the adynamia and cognitive impairment
were the most debilitating symptoms. Hence, a major
depression was diagnosed. Treatment with venlafaxine (up
to 112.5 mg; higher doses were not tolerated) plus agome-
latine (25 mg) together with cognitive-behavioral therapy
was started without sufficient therapeutic success. In the
autumn of 2012, occupational reintegration with reduced
working hours was initiated, but it soon had to be stopped
because of cognitive and also physical exhaustion. The
patient would forget things and fail to understand more
complex tasks. Reaction times were described as extended;
memory was still disturbed, mood depressed, and energy
level reduced.
In January 2014, the patient was admitted to our
hospital. Her somatic history only showed high blood
pressure, which was treated with telmisartan (80 mg),
and a history of a clinically remitted lumbar disc
prolapse. Thyroxine (T4) substitution had been started
at the beginning of 2012 (because TPO and TG
antibodies were elevated in an initial outpatient examin-
ation, whereas thyroid hormones were normal). On
admission to our hospital, 75 μg T4 were taken. The
patient had no history of psychiatric disorders prior to
2011, and her familial history was negative for psychi-
atric, neurological, or autoimmune disorders.
Investigations
Internal and neurological examinations revealed no
relevant abnormalities. Serum analysis showed increased
TPO (804 IU/mL; normal range <34 IU/mL), increased
TG (661.4 IU/mL; normal range <115 IU/mL), and
normal thyroid-stimulating hormone (TSH) receptor
antibodies. The levels of thyroid hormones (triiodothyr-
onine [T3], T4 and TSH) were normal. No antibodies
against intracellular onconeural antigens (Yo, Hu,
CV2/CRMP5, Ri, Ma1/2, SOX1) or intracellular syn-
aptic antigens (GAD, amphiphysin) were found. Cere-
brospinal fluid (CSF) analysis illustrated a slight
blood–brain barrier disturbance (protein 678 mg/L
[reference <450 mg/L], albumin-quotient 7.7 [age-related
reference < 7.3 × 10−3]), a normal white cell blood count
(1/μL), and no intrathecal immunoglobulin synthesis or
oligoclonal bands. Moreover, there were no antibodies
against neuronal cell surface antigens (NMDAR, AMPA-
R, GABA-B-R, VGKC-complex [LGI1, Caspr2]) in the
CSF. Magnetic resonance imaging (MRI) depicted
unspecific supratentorial white matter lesions and frontal
accentuated brain atrophy (Fig. 1). Electroencephalog-
raphy (EEG) was normal. In cognitive testing for
attentional performance (TAP), response time was greatly
reduced and alertness and processing speed were below
average (Fig. 2).
Differential diagnosis
The most important differential diagnosis was major
depression, because the main symptoms of this were
present (lowering of mood, reduction of energy, and
decrease in activity [www.dsm5.org]). The leading
symptoms were cognitive impairments, including
forgetfulness (in particular for short-term memory), so
pre-senile dementia also had to be considered. Other
reasons for inflammatory brain diseases, such as limbic
encephalitis or metabolic disorders, were excluded [2].
Fig. 1 Magnetic resonance imaging (MRI; T2 weighted axial scans) before steroid treatment depicted unspecific supratentorial white matter
lesions and frontal accentuated brain atrophy (upper row). Follow-up MRI 7 months after the start of therapy showed no changes (bottom row)
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Treatment
Intravenous treatment with high dose methylprednisolone
1000 mg over 3 days and 500 mg over 2 days was provided
and well tolerated. Methylprednisolone treatment was
continued with 40 mg orally and tapered by halving the
daily dose every fifth day. Treatment with venlafaxine
(112.5 mg), agomelatine (25 mg), and T4 (75 μg) was
continued unchanged.
Outcome and follow-up
Directly after the high-dose intravenous steroid treatment,
the patient reported reduced cognitive impairment and
improved alertness. Neuropsychological testing confirmed
this rapid improvement with reduced response latencies
in all attention tasks, compared with measurement before
corticosteroid treatment. The basal alertness and process-
ing speed was improved, but still below-average. After
around five weeks, however, the mood and energy levels
had normalized and cognitive impairment disappeared.
After three months, the patient was fully reintegrated at
work without cognitive deficits. In the follow-up testing
for attentional performance (6.5 months after therapy
onset), no relevant neuropsychological deficit remained
(Fig. 2). No changes in the follow-up MRI were detected
(Fig. 1). TPO (440.6 IU/mL; initial 804 IU/mL) and TG
antibodies (581.7 IU/mL; initial 661.4 IU/mL) decreased
but still exceeded the reference limit.
Conclusions
SREAT was first described in 1966 [3], and several case
reports and series have been described since [1, 4, 5]. To
date, no definite diagnostic criteria have been established
for SREAT [6]. Preliminary suggestions remain very
vague with respect to the question of which precise
psychiatric symptoms and syndromes should lead to the
diagnoses when thyroid antibodies are present [7]. Typ-
ical SREAT symptoms include not only neuropsychiatric
syndromes with behavioral or cognitive abnormalities (in
nearly all cases, and including ours), but also tremor
(80 %), stroke-like episodes including transient aphasia
(80 %), myoclonus (65 %), gait ataxia (65 %), seizures
(60 %), and sleep abnormalities (55 %) [1]. Only a few
case reports have documented predominant depressive
symptoms [8–12]. In an overview of five such cases
until 2013, only one presented with isolated affective
symptoms [8]. A case report from our clinic described
a patient with predominant depressive symptoms as
well as an epileptic seizure [9]. Laske et al. described
a 74-year-old female patient with depression and EEG
slowing; after steroid treatment, the affective symptoms
normalized parallel with the EEG [10]. Other psychiatric
cases have been associated with neurological signs, such
as myoclonic jerks or ataxia [11]. SREAT can also be
found in children, often associated with epilepsy, but
in single cases also, with primarily behavioral presen-
tations [12].
Here we present a unique SREAT case, one that
presented clinically only with typical symptoms of a
major depression. Remarkably, the levels of T3, T4, and
TSH were normal, as in some earlier reports [1, 2].
Thus, as pointed out by Castillo et al. it is very unlikely
that T3, T4, and TSH are directly involved in the
Fig. 2 Tests for attentional performance measuring reaction time, divided attention, mental flexibility and working memory before (black bar),
directly after (grey bar) and 6.5 months after cortisone therapy (shaded bar)
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pathophysiology of SREAT. By definition of SREAT,
TPO and also TG antibodies are elevated; however, it is
known that these levels do not correlate with the
relevant symptoms [1]. Antibodies are not considered to
be directly involved in the pathophysiology of SREAT,
because they can also be found elevated in healthy
subjects or in patients with other autoimmune diseases
[2]; also, in line with this, antibodies were still elevated
after remission of depressive symptoms in our patient.
The CSF protein level and albumin quotient in our
subject were increased, as generally described in
earlier reports [1]. EEG findings were normal in our
subject. This contrasts to the about 95 % of SREAT
patients with pathological EEGs in earlier case sum-
maries with generalized slowing, indicating diffuse
brain dysfunction, being the most common finding
[1]. The normal EEG along with the absence of other
neurological deficits in our case might be a marker of
a less severe variant of SREAT or, alternatively, the
consequence of an early initial diagnosis. The MRI
indicated unspecific changes, as noted in the majority
of published cases [1]. In our patient, the presence of
TPO and TG antibodies in combination with an
excellent response to steroid treatment helped to
establish the correct diagnosis after careful exclusion
of other relevant disorders.
In our view, therefore, this case and literature review
illustrates that TPO and TG antibodies should be
performed routinely in depressive patients with atypical
symptoms (discrete neurological symptoms like tremor
or myoclonic jerks) and predominant cognitive impair-
ments, because SREAT may manifest with just symp-
toms of major depression plus increased thyroid
antibodies. Moreover, CSF analysis, EEG, and MRI might
be helpful in establishing the correct diagnosis. This is
particularly important due to a high association between
TPO antibody levels and depressive episodes [13]. In a
queried case of SREAT, a probatory therapy course with
steroids is the only way to clarify the diagnosis.
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